Chemelot Ventures is a venture capital investor in Life Sciences (including drug delivery) and Performance Materials (including polymers). The company aims to further strengthen hubs in these industries on and around the Chemelot Campus and Maastricht Health Campus, two leading European research hubs. Chemelot Ventures continues to actively support its portfolio companies after it has made its investment, drawing on its extensive network in the financial world, the industry and the region. Chemelot Ventures is the successor fund of Limburg Ventures which started in 2004 and made 22 investments.
Beheer Innovatiefonds Provincie Limburg B.V.
Beheer Innovatiefonds Provincie Limburg B.V. was founded in december 2009 by the province of Limburg with the main purpose of giving an impulse to the small and medium enterprises in the Limburg region. Their goal is to realize innovations or to help small and medium enterprises that encounter difficulties by the financial crisis. Since 2009 the fund has invested in innovative companies in various areas, such as Medtech, Functional Food, Materials and Biotech.
Utrecht Holdings is responsible for the patent portfolio and technology transfer activities of Utrecht University and the University Medical Center Utrecht. Utrecht Holdings has started and invested in over 30 spin-out companies and currently holds equity in 24 of those companies. Utrecht Holdings assigned ownership of the CriPec® technology to Cristal Therapeutics, which brings the results of academic research into biotech development to design effective therapeutics for patients. Utrecht Holdings also invested capital in Cristal Therapeutics.
Thuja Capital is an independent venture capital firm focussed on investments in Benelux based early stage companies that aim to develop medical product innovations for prevention, diagnosis, cure or care. Such products include therapeutics, diagnostics, and medical devices, to deliver both healthcare return as well as financial return. Thuja Capital leverages its long-standing experience and extensive network to actively support portfolio companies to strengthen and grow their business.
BioGeneration Ventures invests in seed and early stage Dutch Life Sciences companies. BioGeneration’s team specialises in developing the value of novel and innovative technologies, and in the management of start-up companies. BioGeneration Ventures was co-founded by the Netherlands Genomics Initiative (NGI), Netherlands Organisation for Scientific Research (NWO), the Holding of the University of Leiden, and ABN-AMRO. BioGeneration Ventures cooperates closely with Forbion Capital Partners.
Nedermaas Ventures focuses on pre-seed and seed investment opportunities across a broad spectrum of high technology fields such as for example: Life Sciences, Chemistry, Biotechnology, Automotive and Electronics. Based in Maastricht, the Netherlands, Nedermaas Ventures focuses on start-up companies in, or willing to relocate to the Limburg region, which is strategically situated in the heart of Western Europe. Nedermaas Ventures is managed by LIOF, the Limburg Development and Investment Company.
Aglaia BioMedical Ventures
The Dutch venture capital firm Aglaia – through its Oncology Funds I and II – invests in ground-breaking technologies that have the potential to translate into solutions for the prevention and treatment of cancer. Aglaia is actively involved in the companies it invests in and works closely with scientists and management teams in the early stages of technological development. By translating high-potential research into commercially and clinically successful products Aglaia gives meaning to the concept of impact investing; combining financial and social returns.
DROIA Oncology Ventures
DROIA is a venture capital investor focusing exclusively on oncology therapeutics. Operating from Luxembourg and Belgium, DROIA invests worldwide in early-stage drug development companies that apply novel science and innovative approaches to bring highly promising drug candidates to patients. Through its experienced team of in-house scientists and drug developers, DROIA also supports young companies on scientific and development matters. Funded by private investors, DROIA is dedicated to making a difference in the fight against cancer.